Latest Market Entry News

ASF Group’s subsidiary has secured AUSTRAC registration as a Digital Currency Exchange, positioning itself for future digital asset opportunities while holding off on active trading.

Orthocell has completed its first Remplir™ surgical case in Hong Kong, marking a pivotal step in its Asian commercialisation strategy. The launch at the Hong Kong Orthopaedic Association Congress and partnership with MontsMed set the stage for broader regional growth.

Jade Gas Holdings has appointed industry veteran Chris Newport as Managing Director to spearhead its transition from exploration to production in Mongolia’s coal bed methane sector. Newport’s extensive global experience is expected to accelerate the company’s commercialisation efforts ahead of first gas output.

Argent BioPharma has secured a transformative acquisition of AusCann’s core assets, bolstering its drug delivery technology and manufacturing capabilities ahead of a planned U.S. listing. The company also reported key clinical milestones and refinancing moves in its September 2025 quarterly update.

PARKD Limited has raised $1 million to fund its East Coast expansion, secured a new prefabrication facility in NSW, and landed its first pilot project with McNab Group, marking a pivotal step in its national rollout.

InhaleRx has secured FDA alignment and ethics approvals to progress clinical trials for its inhaled therapies targeting breakthrough cancer pain and panic disorder, with patient dosing set to begin soon.

Merino & Co. initiates a new chapter with leadership changes and a strategic partnership to enter China’s premium apparel market, while investing heavily in growth during Q1 FY26.

Ovanti Limited has made significant strides in its U.S. buy now, pay later (BNPL) expansion, securing a major partnership with Shift4 Payments and raising $8 million to fuel growth.

Cleo Diagnostics has secured positive FDA feedback and nearly 1,600 biobank samples, accelerating its ovarian cancer blood test development ahead of a planned 2026 U.S. market entry.

Avecho Biotechnology advances its pivotal Phase III CBD insomnia trial with 160 patients dosed and secures $2.5 million to accelerate manufacturing and regulatory efforts ahead of a 2026 interim analysis.

EVE Health Group has taken significant strides in commercialising its women’s and men’s health products Dyspro™ and Libbo™, securing regulatory clearances, first patient prescriptions, and raising $1.1 million to support market expansion.

Terra Critical Minerals (ASX, T92) broadens its critical minerals portfolio with new US initiatives and promising exploration in New South Wales and Canada. The company also pursues a US OTC listing to tap North American capital.